Cervical Cancer

Vaccine may lose effectiveness during ovulation

Published in Vaccine Weekly, August 27th, 2003

A new, small study has found that a vaccine against human papillomavirus 16 (HPV16), the virus that causes most cases of cervical cancer, produces antibodies against HPV16 at the site where cervical cancer develops - a promising indication of the vaccine's effectiveness.

But antibody levels appear to decrease around ovulation, raising the possibility that the vaccine may be less effective during that time. The findings appeared in the August 6, 2003, issue of the Journal of the National Cancer Institute.

A vaccine is considered promising if it can produce an immune response (determined by levels of antibodies) at disease-specific sites such as...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2003-08-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry